• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Genentech gets FDA approval for tumour-agnostic drug Rozlytrek pharmaceutical-technology
    August 19, 2019
    The US Food and Drug Administration (FDA) has approved Roche division Genentech’s tumour-agnostic drug Rozlytrek, which targets a specific genetic defect called neurotrophic tyrosine receptor kinase (NTRK).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service